“…Doxycycline is one of the most extensively studied for properties other than its antimicrobial effects (Aminov, 2013;Chen et al, 2019;Stephenson et al, 2018), and excellent blood-brain barrier permeability (Barza et al, 1975;Liu et al, 2001). The drug is known to have a broad range of actions (Garrido-Mesa et al, 2013) including the modification of the neurotransmitters system known to be involved in the pathophysiology of LID such as the cholinergic (Conti et al, 2018;Schlesinger et al, 2004;Schlesinger et al, 2004), serotonergic (Zhang et al, 2006), glutamatergic (Monte et al, 2013) as well as others (Mansson et al, 2007;Munzar et al, 2002). In addition, González-Lizárraga et al (2017) reported that doxycycline reshapes α-synuclein oligomers, inhibits α-synuclein aggregation, and the seeding of new oligomers, thus preventing cytotoxicity in dopaminergic cell lines.…”